Finance · Live Wire
Moderna’s year revolved around concrete steps such as advancing its personalized melanoma vaccine with Merck and pushing its mRNA flu program toward regulators, while quarterly results showed revenue and profit both moving up compared with the prior year. Investors who held Moderna over the past year are up 771.4%, including dividends. If someone had been deciding whether to buy on 15 October 2025, what exactly did they need to believe about this pipeline and its risks?
This theme extends beyond Moderna. See which of 34 healthcare AI stocks may still merit a closer look. The Two Moderna Stories Investors Had To Weigh The shares cost US$27.72 at the start of the period, and anyone looking at Moderna then had to choose between two sharply different stories about where the business might head.
The bullish view pointed to pipeline breadth and close regulatory engagement, and said the stock could be worth a Fair Value of US$44.25. This level was implied by assumptions about revenue growing 4.6% a year and profit margin eventually reaching 14.2%. The bearish narrative saw tighter global scrutiny and pricing pressure, and instead suggested a Fair Value of US$18.15.
This view hinged on the risk that revenue might fall 16.4% a year while Moderna remained dependent on a shrinking COVID vaccine market. NasdaqGS:MRNA 1-Year Stock Price Chart What The 2026 Evidence Did To The Moderna Debate The biggest update for Moderna was progress on its respiratory and oncology pipeline. FDA approval of mFLUSIVA and Q2 2026 revenue of US$145 million, slightly above Q2 2025, gave the bullish case some support.
The business still reported a net loss of US$782 million, so the profitability part of the optimistic story stayed unproven and the evidence cut both ways. The hinge assumption here was that pipeline breadth would translate into healthier cash generation. For any other biotech, you would watch two things quarter by quarter: product approvals and late stage trial results on one side, and whether net losses actually shrink in step with that progress on the other.
What Today's Moderna Price Already Assumes Moderna now trades at US$236. The selected Narrative’s Fair Value sits below that level, even though it credits the broader mRNA pipeline, regulatory momentum, cost cuts and AI tools with reshaping how this business might generate cash over time. That Narrative argues the current quote leans on melanoma and flu vaccines scaling smoothly.
The real question is how its highlighted revenue volatility and competitive pressures intersect with that assumption. "Slowing vaccine sales, higher competition, cost cuts, regulatory pressures, and limited capital flexibility threaten Moderna's revenue stability, pipeline breadth, and long-term earnings growth." The price and this Narrative do not agree. → Uncover what this Narrative says Moderna is actually worth Where Moderna’s Demand Points Next Moderna lives on data. Every vaccine trial rests on immense computing needs.
That demand does not stop at health care. The push to train larger AI models drives constant infrastructure upgrades. One specialist chip designer sits right in that current.
Its hardware and software stack aim to make those training runs feasible. As more AI work moves into high powered data centers, the key winner may not be another drug maker. Instead, a quiet chip name could stand behind both medical breakthroughs and broader AI experimentation.
The case is written up, with the assumptions it depends on. → Discover the AI infrastructure company one Narrative values 56% above its price This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.
We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place We've created the ultimate portfolio companion for stock investors, and it's free. • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free Have feedback on this article? Concerned about the content? Get in touch with us directly.
Alternatively, email editorial-team@simplywallst.com
Source: Simply Wall Street
